Aemetis (NASDAQ:AMTX) Stock Price Expected to Rise, Ascendiant Capital Markets Analyst Says

Aemetis (NASDAQ:AMTX) had its price target boosted by equities researchers at Ascendiant Capital Markets from $18.00 to $19.00 in a report released on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the specialty chemicals company’s stock.

A number of other research analysts have also recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $28.00 price objective on shares of Aemetis in a report on Friday, March 14th. StockNews.com upgraded shares of Aemetis to a “sell” rating in a report on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, Aemetis presently has an average rating of “Hold” and an average price target of $14.56.

Aemetis Price Performance

Shares of NASDAQ AMTX opened at $1.97 on Monday. The stock has a market capitalization of $100.77 million, a P/E ratio of -0.87 and a beta of 1.48. The company has a 50-day moving average price of $2.14 and a 200-day moving average price of $2.67. Aemetis has a 1 year low of $1.50 and a 1 year high of $7.03.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD boosted its holdings in Aemetis by 16.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 38,016 shares of the specialty chemicals company’s stock worth $103,000 after purchasing an additional 5,281 shares during the last quarter. Tower Research Capital LLC TRC raised its position in Aemetis by 128.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 10,407 shares of the specialty chemicals company’s stock worth $28,000 after acquiring an additional 5,859 shares during the period. Barclays PLC raised its position in Aemetis by 14.7% in the fourth quarter. Barclays PLC now owns 54,492 shares of the specialty chemicals company’s stock worth $146,000 after acquiring an additional 6,996 shares during the period. Wells Fargo & Company MN raised its position in Aemetis by 20.0% in the fourth quarter. Wells Fargo & Company MN now owns 45,741 shares of the specialty chemicals company’s stock worth $123,000 after acquiring an additional 7,622 shares during the period. Finally, FMR LLC raised its position in Aemetis by 68.2% in the third quarter. FMR LLC now owns 22,531 shares of the specialty chemicals company’s stock worth $52,000 after acquiring an additional 9,137 shares during the period. 27.02% of the stock is currently owned by hedge funds and other institutional investors.

About Aemetis

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.